Waltermire Robert E.
Insider transactions at 1 company
This page shows all SEC Form 4 filings attributed to Waltermire Robert E.. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.
| Company | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| MDGL | Senior VP, Chief Pharma Dev. | Sale | 1,043 | $341.84 | $356,539 | Mar 5, 2025 |
| MDGL | Senior VP, Chief Pharma Dev. | Sale | 175 | $341.55 | $59,771 | Feb 28, 2025 |
| MDGL | Senior VP, Chief Pharma Dev. | Sale | 103 | $335.24 | $34,530 | Jan 24, 2025 |
| MDGL | Senior VP, Chief Pharma Dev. | Sale | 442 | $273.41 | $120,847 | Jan 17, 2025 |
| MDGL | Senior VP, Chief Pharma Dev. | Option Exercise | 1,900 | $87.09 | $165,471 | Jun 14, 2024 |
| MDGL | Senior VP, Chief Pharma Dev. | Option Exercise | 2,000 | $87.92 | $175,840 | Jun 12, 2024 |
| MDGL | Senior VP, Chief Pharma Dev. | Sale | 1,036 | $231.34 | $239,668 | May 21, 2024 |
| MDGL | Senior VP, Chief Pharma Dev. | Award / Grant | 1,419 | — | — | Jan 23, 2024 |
| MDGL | Senior VP, Chief Pharma Dev. | Tax Withholding | 550 | $243.92 | $134,156 | Jan 16, 2024 |
| MDGL | Senior VP, Chief Pharma Dev. | Option Exercise | 2,000 | $87.92 | $175,840 | Dec 14, 2023 |
| MDGL | Senior VP, Chief Pharma Dev. | Sale | 800 | $219.00 | $175,200 | Dec 12, 2023 |
| MDGL | Senior VP, Chief Pharma Dev. | Sale | 900 | $271.03 | $243,927 | Feb 28, 2023 |
| MDGL | Senior VP, Chief Pharma Dev. | Award / Grant | 5,667 | — | — | Jan 16, 2023 |